Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512954 | 1.00 | ESR1 (0.65) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL8178384 | 1.00 | ESR1 (0.65) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL8166418 | 0.99 | ESR1 (0.66) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL7508532 | 0.99 | ESR1 (0.66) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL7508526 | 0.99 | ESR1 (0.66) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL8165823 | 0.92 | ESR1 (0.66) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL6901059 | 0.92 | ESR1 (0.66) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL7017102 | 0.92 | ESR1 (0.66) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL8177357 | 0.91 | ESR1 (0.66) | ESR1ESR2HRH3CHRM2ADRA2A | |
| SCHEMBL7506156 | 0.91 | ESR1 (0.66) | ESR1ESR2HRH3CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937060-B1 | CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK AS (DK) | 2002-12-11 | — | — | EP | disclosed |
| EP-0937062-B1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK AS (DK) | 2002-12-11 | — | — | EP | disclosed |
| US-6316494-B1 | FOR THERAPY AND PROPHYLAXIS OF BONE LOSS, OSTEOPOROSIS, CARDIOVASCULAR DISEASES, COGNITIVE DISORDERS, MENOPAUSAL SYMPTOMS, INCONTINENCE, OBESITY, DYSMENORRHEA, DYSFUNCTIONAL UTERINE BLEEDING, ACNE, HIRSUTISM, POST-PARTUM LACTATION | NOVO NORDISK A/S (DK) | 2001-11-13 | — | — | US | disclosed |
| US-20010021710-A1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-6043269-A | ESTROGEN AGONISTS | NOVO NORDISK A/S (DK) | 2000-03-28 | — | — | US | disclosed |
| EP-0937062-A1 | NOVEL $i(CIS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1999-08-25 | — | — | EP | disclosed |
| EP-0937060-A1 | NOVEL $i(CIS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998018779-A1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1998-05-07 | — | — | WO | disclosed |
| WO-1998018776-A1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | NOVO NORDISK A/S (DK) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021710-A1 | NOVEL CIS-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | CYP19A1, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885HRH3 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.